RE:RE:RE:CAR-T updateApril 12, 2024 - Roche subsidiary Genentech has terminated a cell therapy partnership with Adaptimmune Therapeutics worth up to $3 billion biobucks. The collaboration, inked in 2021, was a licensing deal focused on the development of two types of allogeneic T-cell therapies: off-the-shelf therapies directed to up to five targets and personalized therapies using αβ T-cell receptors isolated from a patient, with these therapies being administered to the same patient.
https://www.fiercebiotech.com/biotech/one-day-after-confirming-staff-cuts-genentech-axes-adaptimmune-cell-therapy-deal
In November 2023 ONCY reported that AWARE-1 patient samples showed that in the first three days after dosing, pelareorep upregulated tumor PD-L1 expression in the tumors, induced the generation and expansion of T cell clones, and promoted the tumor infiltration of CD8+ T cells.
https://www.prnewswire.com/news-releases/oncolytics-biotech-and-solti-present-further-positive-pelareorep-translational-data-at-sitc-301977019.html